Pharmacokinetics, Safety and Tolerability of Olaparib and Temozolomide for Recurrent Glioblastoma: Results of the Phase I OPARATIC Trial
Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)
There are 2 important points from this study:
1. They tested a rat model to see if olaparib can cross the blood brain barrier. This is a standard test that is used for most drugs. They found that this drug does not cross the blood brain barrier in rats. Then they tested in people by giving the drug before a surgery and testing the tumor sample removed and found that 100% of the time it does cross the blood brain barrier and gets into the human brain. This shows that we really can't trust the mouse models for BBB penetration and we need these human tests.
2. Olaparib is a PARP inhibitor (which is approved for other types of cancer so it is readily available off label) and they found that in the test tube it acts as a radiation sensitizer at the concentrations they found in the human testing of tumor samples. They report 36% of patients with recurrent glioblastoma were progression free at 6 months, which shows it has some effect and needs to be studied further to see how best to use it!
Posted on: 04/30/2020
Click HERE to return to brain tumor news headlines